Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss Transcript
Veradermics, Incorporated MANE
$144.46
▲ +0.35%
(+$0.51)
📅 Earnings This Week
Open
$141.86
Prev Close
$143.95
Day Range
$141.81 – $145.99
52W Range
$32.00 – $146.58
Market Cap
$5.80B
Beta
0.39
EPS (TTM)
$-3.78
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 2026-02-04 |
| Shares Out. | 41,780,000 |
| Website | veradermics.com ↗ |
| Phone | 18009279800 |
| Employees | 21 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$23.5M |
| Total Assets | $825.7M |
| Total Liabilities | $12.1M |
| Equity | $813.6M |
About Veradermics, Incorporated
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
Veradermics, Incorporated is a publicly traded company under the ticker symbol MANE on the NEW YORK STOCK EXCHANGE, INC., operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-11-01)
📰 Latest News for MANE
Veradermics stock rises on 12-month hair growth trial data
Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss
Veradermics Announces Topline Results From Registration-Directed Phase 2/3 Trial Of VDPHL01, Demonstrating Efficacy In Male Pattern Hair Loss
Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics (MANE) Late Stage Trial Narrative Keeps Undervalued View Alive
Connecticut Innovations Generates Record Breaking $51.4 Million in Venture Proceeds in Q1 FY27